Evidence map›Paper›PMID 39764566›Full record

ReviewMedComm2025

RNA N4-acetylcytidine modification and its role in health and diseases.

Qiang Wang, Yixiao Yuan, Qiang Zhou, YingDong Jia, Jing Liu, GuangJun Xiao, Chunhong Li, Xiulin Jiang

Abstract readReview
In one paragraph

Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Review
  2. Identifying RNA acInterdisciplinary sciences, computational life sciences · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. The NAT10/acCell communication and signaling : CCS · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. NSUN5 and RNA mFrontiers in cell and developmental biology · 2026
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qiang WangGastrointestinal Surgical Unit Suining Central Hospital Suining Sichuan China.
Yixiao YuanDepartment of Hepatobiliary Surgery The First Affiliated Hospital of Chongqing Medical University Chongqing China.
Qiang ZhouDepartment of Oncology Suining Central Hospital Suining Sichuan China.
YingDong JiaGastrointestinal Surgical Unit Suining Central Hospital Suining Sichuan China.
Jing LiuGastrointestinal Surgical Unit Suining Central Hospital Suining Sichuan China.
GuangJun XiaoDepartment of Clinical Laboratory Medicine Suining Central Hospital Suining Sichuan China.
Chunhong LiDepartment of Oncology Suining Central Hospital Suining Sichuan China.
Xiulin JiangDepartment of Medicine UF Health Cancer Center University of Florida Gainesville Florida USA.ORCID https://orcid.org/0000-0001-7986-0465

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

N4-acetylcytidine (ac4C) modification is a crucial RNA modification widely present in eukaryotic RNA. Previous studies have demonstrated that ac4C plays a pivotal role in viral infections. Despite numerous studies highlighting the strong correlation between ac4C modification and cancer progression, its detailed roles and molecular mechanisms in normal physiological processes and cancer progression remain incompletely understood. This review first outlines the key regulatory enzyme mediating ac4C modification, N-acetyltransferase 10 (NAT10), including its critical roles in regulating RNA stability, transcriptional efficiency, and translational fidelity. Additionally, it systematically summarizes the essential functions and mechanisms of ac4C modification in normal biological processes, including stem cell fate determination, spermatogenesis and oogenesis, embryonic development, cellular senescence, and bone remodeling. Furthermore, this review delves into the central roles and molecular mechanisms of ac4C modification in regulating malignant proliferation, cell cycle arrest, EMT, drug resistance, cell death, cancer metabolism, and tumor immunotherapy. It also emphasizes the potential of NAT10 as a prognostic biomarker and its therapeutic potential as a target for disease treatment. In summary, this review clarifies the multifaceted roles of ac4C modification in both health and disease and explores NAT10-targeted therapies with the aim of advancing cancer research and improving patient outcomes.

Indexed as

human cancerN4‐acetylcytidineNAT10pathologyphysiologyRNA modificationtumor immunotherapy

Identifiers

PMID39764566
PMCPMC11702397

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.